- Home
- ASND vs NLY Comparison
ASND vs NLY Comparison
Compare ASND & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | NLY |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | Denmark | United States |
| Employees | N/A | 212 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 16.3B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASND | NLY |
|---|---|---|
| Price | $210.87 | $21.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $281.50 | $23.82 |
| AVG Volume (30 Days) | 532.4K | ★ 5.9M |
| Earning Date | 05-12-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 12.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $96.35 | $188.83 |
| Revenue Next Year | $44.91 | $2.40 |
| P/E Ratio | ★ N/A | $7.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $161.09 | $18.64 |
| 52 Week High | $250.74 | $24.52 |
Technical Indicators
Market Signals| Indicator | ASND | NLY |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 37.82 |
| Support Level | $190.56 | $20.58 |
| Resistance Level | $218.88 | $22.02 |
| Average True Range (ATR) | 8.26 | 0.33 |
| MACD | -3.26 | -0.04 |
| Stochastic Oscillator | 0.19 | 17.47 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
About NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.